The Effect of Chloroquine in the Treatment of Patients With Dengue
Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dengue
Intervention: Placebo (Drug); Chloroquine (Drug)
Phase: Phase 1/Phase 2
Status: Active, not recruiting
Sponsored by: University of Sao Paulo Official(s) and/or principal investigator(s):
Benedito AL Fonseca, PhD, Principal Investigator, Affiliation: São Paulo University Medical School at Ribeirão Preto
Summary
The objective of this study was to evaluate the effect of chloroquine in the treatment of
patients with dengue.
Clinical Details
Official title: The Effect of Chloroquine in the Treatment of Patients With Dengue
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Duration of the disease
Secondary outcome: Intensity and days of fever and symptoms
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients suspected of having dengue disease
- Patients were included in the study if they presented with fever and at least two
other symptoms, such as:
- headache
- pain behind the eyes
- muscle and bone or joint pains
- nausea
- vomiting
- rash associated to dengue for less than 72 hours
Exclusion Criteria:
- Pregnant
- Younger than 18-years old
- Either cardiac or neurologic disease
Locations and Contacts
São Paulo University Medical School at Ribeirão Preto, Ribeirão Preto, SP 14048.900, Brazil
Additional Information
Starting date: February 2008
Last updated: February 23, 2009
|
